Skip to main content
D

DIMERIX LIMITED — Investor Relations & Filings

Ticker · DXB ISIN · AU000000DXB7 ASX Professional, scientific and technical activities
Filings indexed 1,124 across all filing types
Latest filing 2017-12-13 Regulatory Filings
Country AU Australia
Listing ASX DXB

About DIMERIX LIMITED

https://dimerix.com/

Dimerix Limited focuses on the development of therapeutic treatments for inflammatory diseases, with a primary emphasis on kidney and respiratory conditions. The company utilizes its proprietary Receptor-Heteromer Investigation Technology (DMX-Technology) to identify and validate G protein-coupled receptor (GPCR) targets. Its lead candidate, DMX-200, is a chemokine receptor (CCR2) antagonist currently in Phase 3 clinical trials for the treatment of Focal Segmental Glomerulosclerosis (FSGS). The company is also advancing DMX-700 for Chronic Obstructive Pulmonary Disease (COPD) and exploring applications for diabetic kidney disease. The core strategy involves targeting multiple signaling pathways simultaneously to address unmet medical needs in chronic inflammatory and fibrotic diseases.

Recent filings

Filing Released Lang Actions
Proteomics partnership to improve treatment of CKD 2 pages 133.6KB
Regulatory Filings
2017-12-13 English
Proteomics partners diagnostic test with Dimerix kidney drug 3 pages 237.4KB
Regulatory Filings
2017-12-13 English
Dispatch of Offer Document and Entitlement and Forms 1
Regulatory Filings
2017-12-12 English
Audio interview with CEO 2 pages 431.9KB
Regulatory Filings
2017-12-10 English
Entitlement Offer to raise $5.5 million 3 pages 48.5KB
Regulatory Filings
2017-12-05 English
Cleansing Notice 2 pages 206.2KB
Regulatory Filings
2017-12-05 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.